News - Generics
Dr Reddy's Laboratories appoints Umang Vohra head of North America generics ...
27 November 2012
"Umang Vohra, who was the CFO of the company for the past four years, will take over the role of Executive Vice- President and Head of North America generics business from January 2013," Dr Reddy's Laboratories (DRL) said in a statement today.
Click on the link to read the full article at Economic Times (This link will open in a new window)Rising Pharma launches generic Cleocin Pediatric in US market
27 November 2012
Rising Pharmaceuticals Inc., a finished dosage form generics subsidiary of ACETO Corporation, has launched the generic version of the 75mg/5mL strength of Clindamycin Palmitate Hydrochloride for oral solution, USP (pediatric), an FDA approved generic ...
Click on the link to read the full article at pharmabiz.com (This link will open in a new window)Expiring Patents Could Mean Huge Profits for This Little-Known Stock
26 November 2012
This is because Actavis was already a formidable player in the global generics market, with $2.5 billion in annual sales, more than 1,000 products on the market, several hundred new products in the pipeline and operations in 40 countries. Some of its ...
Click on the link to read the full article at NASDAQ (This link will open in a new window)ACETO Subsidiary, Rising Pharmaceuticals, to Launch Generic Version of ...
26 November 2012
PORT WASHINGTON, N.Y., Nov 26, 2012 (Menafn - GlobeNewswire via COMTEX) --ACETO Corporation ACET, a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, ...
Click on the link to read the full article at MENAFN.COM (This link will open in a new window)Survey: 94% favour generic medicines
26 November 2012
The 67% of adults using generic medicines is an increase of 35% on 2009 findings, with a majority (54%) of those surveyed citing cost as the dominant reason for switching to generics. The survey also found that 91% believe generics are as safe and ...
Click on the link to read the full article at Irish Examiner (This link will open in a new window)Ranbaxy recalls generic Lipitor doses
26 November 2012
TRENTON, N.J. -- Ranbaxy Pharmaceuticals Inc. has recalled dozens of lots of its generic version of cholesterol drug Lipitor because some may contain tiny glass particles, the latest in a string of manufacturing deficiencies that once led U.S ...
Click on the link to read the full article at HeraldNet (This link will open in a new window)Years behind Ontario, BC Deepens Savings on Generic Drugs
26 November 2012
On April 1, 2013, B.C. will start paying for generics at 25 per cent of the price of the equivalent brand name drug. A year later it will bump that down further to 20 per cent, which Health Minister Margaret MacDiarmid said "as far as we know will be ...
Click on the link to read the full article at TheTyee.ca (This link will open in a new window)Generic-drug prices to drop April 1, province says
24 November 2012
British Columbians will start paying less for generic prescription drugs beginning next year, the provincial government confirmed Friday as it announced the latest element of its plan to control the costs of generics. The new pricing comes into effect ...
Click on the link to read the full article at Vancouver Sun (This link will open in a new window)Generic drugs will be cheaper starting next year, says BC government
24 November 2012
British Columbians will start paying less for generic prescription drugs beginning next year, the provincial government confirmed Friday as it announced the latest element of its plan to control the costs of generics. The new drug pricing comes into ...
Click on the link to read the full article at Vancouver Sun (This link will open in a new window)Another Generic from Dr. Reddy's - Analyst Blog
23 November 2012
Dr. Reddy's Laboratories ( RDY ) recently launched its generic version of Pfizer's ( PFE ) pulmonary arterial hypertension (PAH) drug, Revatio (sildenafil) tablets. We note that Dr. Reddy's is not the only company to launch a generic version of Revatio ...
Click on the link to read the full article at NASDAQ (This link will open in a new window)
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
